Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Orion Oyj's 3-Year RORE % for the quarter that ended in Mar. 2026 was 65.50%.
The industry rank for Orion Oyj's 3-Year RORE % or its related term are showing as below:
ORINF's 3-Year RORE % is ranked better than 85.36% of 936
companies
in the Drug Manufacturers industry
Industry Median: 3.075
vs ORINF: 65.50
Orion Oyj (OTCPK:ORINF) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Orion Oyj 3-Year RORE % Related Terms
Orion Oyj 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Orion Oyj's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Orion Oyj's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Oyj 3-Year RORE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orion Oyj's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Orion Oyj's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Orion Oyj (ORINF) has a 3-Year RORE % of 65.50 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Orion Oyj and its competitors. According to the industry distribution chart, Orion Oyj ranks #137 out of 936 companies in the Drug Manufacturers industry, placing it in the top 14.6%.
Is Orion Oyj's 3-Year RORE % too high?
Orion Oyj's current 3-Year RORE % is 65.50. The Drug Manufacturers industry median 3-Year RORE % is 3.08. Orion Oyj's value of 65.50 is 2030.1% above this industry median. Based on the distribution chart, Orion Oyj ranks #137 out of 936 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Orion Oyj has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does Orion Oyj's 3-Year RORE % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Orion Oyj ranks #137 out of 936 companies for 3-Year RORE %. This places Orion Oyj in the top 15% of its industry — outperforming the majority of peers. The industry median 3-Year RORE % is 3.08. Orion Oyj's value of 65.50 is 2030.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 3.08, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Oyj's current 3-Year RORE % of 65.50 is 2030.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Orion Oyj and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 3.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Oyj's current 3-Year RORE % is 65.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Oyj stock overvalued right now?
Orion Oyj (ORINF) has a current 3-Year RORE % of 65.50. The stock's GF Value™ is $80.88, compared to a current price of $82.75 — trading 2.3% above its estimated fair value. The current 3-Year RORE % is 65.50 and 2030.1% above the Drug Manufacturers industry median of 3.08. Orion Oyj's overall GF Score™ is 97/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Orion Oyj (ORINF), the current 3-Year RORE % is 65.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Oyj (ORINF) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Oyj stock appears to be overvalued.
The current stock price of $82.75 is trading 2.3% above its estimated GF Value™ of $80.88.
Key valuation signals for ORINF:
3-Year RORE %: 65.50
GF Value™: $80.88 vs. price of $82.75 (2.3% above fair value)
Industry Position: 2030.1% above the Drug Manufacturers median (#137 of 936)
No single metric tells the full story. See the ORINF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Oyj is a globally operating Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company predominantly focuses on treatments for central nervous system disorders, oncology, and respiratory diseases. Orion's customers include specialists and general practitioners, veterinarians, pharmacies, hospitals, and laboratories. The company mainly serves Finland but also has a presence in other European countries, North America and other countries.
97GF Score
Get the complete analysis for ORINF
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORINF has been successfully added to your 
